the future of hcv therapy ns4b as an antiviral target未来的丙肝病毒疗法ns4b作为抗病毒药物的目标.pdf

Viruses 2010, 2, 2481-2492; doi:10.3390/v2112481 OPEN ACCESS viruses ISSN 1999-4915 /journal/viruses Review The Future of HCV Therapy: NS4B as an Antiviral Target Hadas Dvory-Sobol 1, Philip S. Pang 1,2 and Jeffrey S. Glenn 1,3,* 1 Department of Medicine, Division of Gastroenterology and Hepatology, Stanford University School of Medicine, CCSR 3115A, 269 Campus Drive, Palo Alto, CA, USA; E-Mails: hadasds@ (H.D.-S.); pspang@ (P.S.P.) 2 Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA, USA 3 Veterans Administration Medical Center, 3801 Miranda Avenue, Palo Alto, CA, USA * Author to whom correspondence should be addressed; E-Mail: jeffrey.glenn@; Tel.: +1-650-725-3373; Fax: +1-650-723-3032. Received: 19 August 2010; in revised form: 28 September 2010 / Accepted: 13 October 2010 / Published: 10 November 2010 Abstract: Chronic hepatitis C virus (HCV) infection is a major worldwide cause of liver disease, including cirrhosis and hepatocellular carcinoma. It is estimated that more than 170 million individuals are infected with HCV, with three to four million new cases each year. The current standard of care, combination treatment with interferon and ribavirin, eradicates the virus in only about 50% of chronically infected patients. Notably, neither of these drugs directly target HCV. Many new antiviral therapies that specifically target hepatitis C (e.g. NS3 prot